Dr. Nawal Helmi completed her bachelor’s degree in Biochemistry in 2004 and her master’s degree in Genetics and Pharmacology in 2008 from King Abdul-Aziz University (Jeddah). During her time at King Abdul-Aziz University Hospital, she volunteered and witnessed the suffering of patients with sickle cell anaemia. This experience motivated her to dedicate her efforts to alleviating the suffering of sickle cell anaemia patients worldwide. In pursuit of her goal, Dr. Helmi pursued a Ph.D. from the University of Leicester, which she successfully completed in 2014. Her doctoral dissertation focused on "The Effect of Perfluorocarbon Therapy in Streptococcus pneumoniae-Infected Sickle Cell Mice." Her research during her Ph.D. emphasized the interplay between immunology and haematology. Specifically, she investigated how perfluorocarbon therapy, a treatment utilizing synthetic compounds with high gas-carrying capacity, could impact the immune response and haematological parameters in sickle cell mice infected with Streptococcus pneumoniae. This study received recognition through the esteemed "Best 50 Research in the University of Leicester" award for two consecutive years. Currently, Dr. Helmi serves as an Associate Professor of Biochemistry at Jeddah University in Jeddah. In her role, she leads and supervises a team of students working on projects related to haematology, oncology, and autoimmune diseases. Among these projects, Dr. Helmi and her team are actively engaged in research involving immunotherapy, with a particular focus on targeting the CD47 protein. By utilizing anti-CD47 monoclonal antibodies in combination with Imatinib, they aim to enhance the effectiveness of chronic myeloid leukaemia (CML) treatment. There in vitro study involves assessing various parameters such as cell viability, proliferation, apoptosis, and immune cell interactions to better understand the impact of these treatments on CML cells. Dr. Helmi and her team aspire to improve patient outcomes by promoting cancer cell death and enhancing immune cell-mediated clearance of CML cells through this innovative approach